Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2024 issues

AI virtuosos reveal ins, outs, hopes, doubts

Four views of artificial intelligence in pathology and laboratory medicine. That’s what panelists provided for attendees at the 7th Clinical Lab 2.0 workshop in late February in Chicago. The University of Michigan’s Ulysses G. J. Balis, MD, spoke of AI’s use in laboratory operations and diagnostics. Tom Neufelder of Beckman Coulter spotlighted its use in instruments and postanalytically. Gaurav Sharma, MD, of Henry Ford Health is the skeptic, and the University of Pittsburgh’s Michael Becich, MD, PhD, is the rabid enthusiast who is working to unite pathology’s reports and calls himself a data plumber.

Next-gen sequencing—the anxiety, optimism, and goal

May 2024—Laboratory-developed testing as it relates to next-generation sequencing was up first in the NGS conversation led online by CAP TODAY publisher Bob McGonnagle on March 19. Other topics: in-house NGS testing, artificial intelligence, and bioinformatics. “There’s a reality now where bioinformatics is solid, stable, and reliable,” said José Luis Costa, PhD, of Thermo Fisher Scientific.

Cytopathology in focus—POU2F3: A new IHC marker for small cell lung cancer with low neuroendocrine marker expression

May 2024—Classically, immunohistochemical expression of small cell lung cancer (SCLC) is characterized by strong expression of neuroendocrine markers, notably synaptophysin, chromogranin A, insulinoma-associated protein 1 (INSM1), and CD-56. However, up to 20 percent of SCLCs demonstrate low or no expression of neuroendocrine (NE) markers by IHC and are termed “NE-low/negative.”

From the President’s Desk

May 2024—You may have read my column in the March issue about how the CAP is taking care of the next generation of pathologists by helping and engaging our new-in-practice colleagues. If you’re a more seasoned pathologist, you may be wondering: What about me?

Confronting diagnostic gaps in fungal infection

April 2024—It’s readily apparent in the patient populations at Johns Hopkins Hospital, where he is director of the mycology laboratory. Especially concerning is the increase in Candida auris following the height of the COVID-19 pandemic, both in terms of colonization and infection cases, says Dr. Zhang, who is also associate professor of pathology, Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine. “Since 2022, we suddenly saw an uptick in Candida auris cases across the Johns Hopkins Health System.”

Clinical pathology selected abstracts

May 2024—Massive hemorrhage is a major cause of death in children, and the mortality rate from life-threatening hemorrhage is estimated to be 20 to 51 percent. To counter this high mortality rate, clinicians have sought to standardize massive transfusion protocols and hemostatic resuscitation, ensuring that protocols support balanced blood-based resuscitation or the use of low titer group O whole blood, or both. These protocols may include using the lysine analogue antifibrinolytics tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in children with life-threatening hemorrhage (LTH). However, use of these antifibrinolytics is much more common in adult trauma patients. Study data suggest that TXA may increase survival outcomes in adults with traumatic injury, postpartum hemorrhage, nontraumatic intracranial hemorrhage, and all-cause bleeding.

Anatomic pathology selected abstracts

May 2024—The Bethesda System for Reporting Thyroid Cytopathology described four subclasses of atypia within the atypia of undetermined significance category: nuclear (AUS-Nuc), architectural (AUS-A), oncocytic (AUS-Onc), and atypia not otherwise specified (AUS-NOS). Accumulating evidence supports the use of a binary AUS subclassification scheme based primarily on the presence of nuclear atypia only. The authors conducted a study to compare the risk stratification of binary versus four-tier AUS subclassification systems among AUS nodules with molecular or histologic follow-up, or both. The study included thyroid aspirates classified as AUS and tested using Afirma (Veracyte Inc.) between June 2013 and July 2021. Histological classification was considered the final outcome for resected nodules.

Molecular pathology selected abstracts

May 2024—Immunotherapy has revolutionized cancer treatment by recruiting the patient’s immune system to detect and destroy cancer cells. Immunotherapy often involves immune checkpoint blockade (ICB) agents, which target negative regulators of T-cell activation, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1). Although ICB is used to treat a variety of cancer types, patients’ response to therapy is often unpredictable, and biomarkers such as tumor mutation burden, mismatch repair deficiency, and IHC for PD-L1 have limitations for assessing ICB response. Consequently, there is great interest in discovering additional biomarkers that will improve the ability to predict clinical response to ICB. Recent studies have explored the hypothesis that there may be a correlation between a person’s gut microbiome and therapeutic response.

MARKETPLACE

TRENDING